NeuroPerspective

Our monthly journal covering the cutting-edge therapies being developed for disorders of the central nervous system, including Alzheimer's, Parkinson's, stroke, brain injury, schizophrenia, and depression--and the companies pursuing them. It enjoys worldwide readership and recognition for its 'no-holds-barred' evaluations.

1 year subscription: $2390

---

Startup, academic, individual rates available: Contact us at info@niresearch.com

order online

downloads:

• order form
• sample issue (June 2013: Three Orphans: Fragile X, Rett Syndrome, Spinal Muscular Atrophy)
• index of issues

NeuroLicensing 2013

NeuroLicensing 2013 assesses current trends in deal parameters, and focuses on the major and midsize companies who are involved in CNS licensing, as well as some smaller alternative possibilities. Opportunities and licensing agendas are appraised. This provides a vital targeting resource for licensing efforts on both sides of the transaction, for both potential licensors and licensees.